Delivery Order SPE2DB20D1100-SPE2DB25FD6S1
- Not listed
- The Defense Logistics Agency awarded a $21,976.95 delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Dupixent 300 mg/2 ml pen injectors (2 ml units). This is a firm fixed price, non-set-aside contract with a completion date of July 29, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat moderate-to-severe eczema, asthma, chronic rhinosinusitis with nasal...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Dupixent 300 mg/2 mL pen injectors with a ceiling value of $5,051.46. This is a firm fixed-price, non-set-aside contract with an ultimate completion date of July 21, 2025, and performance will take place at the vendor's corporate office location in Conshohocken, Pennsylvania. Dupixent is a biologic medication used to treat conditions including atopic dermatitis, eczema, and...
- The Defense Logistics Agency awarded a delivery order valued at $10,835.98 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen injectors on July 23, 2025, with an ultimate completion date of July 24, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. Dupixent is a biologic medication used to treat various inflammatory conditions,...
- The Defense Logistics Agency awarded a delivery order valued at $10,813.19 to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors on August 13, 2025, with an ultimate completion date of August 14, 2025. This is a firm fixed price, competitively awarded delivery order with no set-aside designation. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. Dupixent is a biologic medication used to treat moderate-to-severe eczema, asthma, and...
- The Defense Logistics Agency awarded a delivery order valued at approximately $35.9K to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pen injectors on July 29, 2025. This firm fixed price, non-set-aside contract is scheduled for completion by July 30, 2025, with performance taking place at the contractor's corporate office in Conshohocken, Pennsylvania. Dupixent is a prescription biologic medication commonly used to treat moderate-to-severe atopic dermatitis,...
- The Defense Logistics Agency awarded a delivery order valued at $9,380.82 to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 mL pen injectors on August 8, 2025, with an ultimate completion date of August 11, 2025. This firm fixed-price delivery order represents a non-competitive, non-set-aside award and is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat moderate-to-severe atopic dermatitis,...
- The Defense Logistics Agency awarded a $26,328.21 delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Dupixent 300 mg/2 ml pen injectors (2 ml units). This is a firm fixed price, non-set-aside contract with an ultimate completion date of August 14, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat moderate-to-severe atopic dermatitis,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors with a firm fixed price of $3,418.92 and an ultimate completion date of August 15, 2025. This non-set-aside award was issued on August 14, 2025, with performance to be completed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat moderate-to-severe atopic dermatitis, eosinophilic asthma, and chronic...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Dupixent 300 mg/2 ml pen injectors with a ceiling value of $11,573.00. This competitively awarded, firm fixed-price delivery order is scheduled for completion by August 11, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat moderate-to-severe eczema, asthma, and other...
- The Defense Logistics Agency awarded a $14,369.52 delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Dupixent 200 mg/1.14 mL pen injectors. This competitively awarded, non-set-aside contract carries a firm fixed price structure with an ultimate completion date of July 25, 2025, and will be performed at the contractor's corporate office in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic immunosuppressant medication used to treat moderate-to-severe...
- SPE2DB20D1100Indefinite Delivery Contract
- SPE2DB20D1100-SPE2DB25FD6S1Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $8,079.03 to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Dupixent 300 mg/2 mL pen injectors. This is a firm fixed price, non-set-aside contract with a completion date of July 29, 2025, to be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. Dupixent is a biologic medication used to treat moderate-to-severe atopic dermatitis, eosinophilic asthma, and other inflammatory conditions, and this delivery order represents a routine pharmaceutical procurement supporting military healthcare operations. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. As a major pharmaceutical distributor and critical vendor in the federal medical supply chain, AmerisourceBergen Drug Corp maintains an extensive portfolio of brand-name and generic medications, vaccines, and medical supplies across multiple therapeutic domains to support Defense Health Agency, U.S. Coast Guard, and other military healthcare systems globally. The company's competitive performance under its prime vendor agreement demonstrates its capability to fulfill specialized pharmaceutical procurement requirements efficiently.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $8.1k | 7/28/25 |